Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment



Anti-Cancer Agents in Medicinal Chemistry, 13(7): 1014-1024.

Author(s): Aamir Ahmad, Bernhard Biersack, Yiwei Li, Dejuan Kong, Bin Bao, Rainer Schobert, Subhash B. Padhye and Fazlul H Sarkar.

Affiliation: Departments of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 740 HWCRC Bldg, 4100 John R. Street, Detroit, MI 48201 USA.

Abstract

Cancer remains a difficult disease to manage because of the deregulation of numerous signaling pathways that are associated with its development and progression. One such pathway is the phosphoinositide 3-kinase (PI3K) – protein kinase B (Akt) - mammalian target of rapamycin (mTOR) signaling network, which is known to be associated with poor prognosis in many human cancers. Targeted inhibition of this signaling network in vitro, in vivo and in clinics has suggested this to be an effective strategy for the inhibition of cancer cells’ proliferation and metastases. Towards this end, the use of natural agents for therapeutic intervention has attracted renewed interest because of their non-toxic effects as well as their ability to modulate multiple pathways. Investigations involving isoflavones have suggested a potent anticancer activity of these compounds against multiple factors in the PI3K/Akt/mTOR pathway. In addition to their use as therapeutic agents against various cancers, there is evidence to support the role of isoflavones in potentiation of radiation therapy as well as the anticancer action of other conventional therapeutic drugs. In this review article, we discuss our current understanding of the regulation of PI3K/Akt/mTOR signaling pathways by isoflavones, which could be responsible for their observed in vitro and in vivo activity against human cancers.

Keywords:

Isoflavones, anticancer therapy, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), genistein, deguelin, sensitization.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 13
Issue Number: 7
First Page: 1014
Last Page: 1024
Page Count: 11
DOI: 10.2174/18715206113139990117
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science